Temasek Leads $85M Series B Round In Chinese Biotech Start-Up

Login to View

Gracell Biotechnologies, a Chinese biotech start-up that focuses on cellular gene therapy, has raised a US$85 million series B financing round led by Singapore’s state investment firm Temasek, according to an announcement released on Monday.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in

China Money Network Subscription